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Abstract
Objective: In recent years, vitamin D has been shown to possess a wide range of immunomodulatory effects. Although
there is extensive amount of research on vitamin D, we lack a comprehensive understanding of the prevalence of vitamin D
deficiency or the mechanism by which vitamin D regulates the human immune system. This study examined the prevalence
and correlates of vitamin D deficiency and the relationship between vitamin D and the immune system in healthy
individuals.
Methods: Healthy individuals (n = 774) comprised of European-Americans (EA, n = 470), African–Americans (AA, n = 125),
and Native Americans (NA, n = 179) were screened for 25-hydroxyvitamin D [25(OH)D] levels by ELISA. To identify the most
noticeable effects of vitamin D on the immune system, 20 EA individuals with severely deficient (,11.3 ng/mL) and
sufficient (.24.8 ng/mL) vitamin D levels were matched and selected for further analysis. Serum cytokine level
measurement, immune cell phenotyping, and phosphoflow cytometry were performed.
Results: Vitamin D sufficiency was observed in 37.5% of the study cohort. By multivariate analysis, AA, NA, and females with
a high body mass index (BMI, .30) demonstrate higher rates of vitamin D deficiency (p,0.05). Individuals with vitamin D
deficiency had significantly higher levels of serum GM-CSF (p = 0.04), decreased circulating activated CD4+ (p = 0.04) and
CD8+ T (p = 0.04) cell frequencies than individuals with sufficient vitamin D levels.
Conclusion: A large portion of healthy individuals have vitamin D deficiency. These individuals have altered T and B cell
responses, indicating that the absence of sufficient vitamin D levels could result in undesirable cellular and molecular
alterations ultimately contributing to immune dysregulation.
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Introduction
The prevalence and significance of vitamin D deficiency has
received significant attention in recent years. Reports of vitamin D
deficiency prevalence vary depending on the population demo-
graphics [1]. Special emphasis has been placed on the prevalence
of deficiency in populations thought to be at higher risk including
individuals living at northern latitudes, the elderly, postmenopaus-
al women receiving treatment for osteoporosis, and ethnic
minorities, where incidences of 25-hydroxyvitamin D [25(OH)D]-
deficiency range from 30% to .50% [1 7]. Several factors
contribute to the elevated risk of vitamin D deficiency including
ethnicity, gender, age, residence in areas of low natural ultraviolet
B irradiation (UVB), increased body mass index (BMI), and
genetic variations in vitamin D metabolism pathways and vitamin
D binding protein [5,7,8,9,10,11,12,13,14]. However, due to the
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wide spread variability of reported vitamin D deficiency, it is of
interest to further examine potential risk factors for and the
prevalence of vitamin D deficiency in a multiethnic cohort in the
same location with a range of UVB seasonal variation, such as
central Oklahoma at the 35oN latitude.
While the skeletal effects of vitamin D deficiency are well
accepted, a growing body of research has begun to examine
extraskeletal effects of vitamin D [1,15,16,17,18,19,20,21,22,23,
24,25,26]. Vitamin D deficiency has been associated with cancer,
cardiovascular disease, autoimmune diseases, type 2 diabetes, and
infectious diseases particularly tuberculosis (TB) infection [27,28],
as well as all-cause mortality [1,18,19,22,23,24,25,29,30,31,32,
33,34,35]. Vitamin D receptors (VDRs) and vitamin D 1-a
hydroxylase (CYP27B1), a necessary enzyme for vitamin D
activation, is found in activated lymphocytes, macrophages, and
dendritic cells and suggests an immunomodulatory role of vitamin
D [26,36,37]. Previous in vitro and ex vivo studies demonstrate that
vitamin D can effectively enhance innate anti-microbial responses
and suppress adaptive immunity [38,39,40,41].
Immunomodulatory roles of vitamin D can extend to the
regulation of the proliferation and development of many immune
cell subsets. Vitamin D modulates adaptive immune responses by
inhibiting the T helper (Th)1 and Th17 cells [42,43,44,45] and
altering the activities of naı¨ve B cells and antigen presenting cells
(APCs) in both human and mouse [46,47,48]. Vitamin D has been
demonstrated to skew the T cell populations toward increased
numbers of regulatory T cells (Tregs) [49,50,51] and can enhance
and maintain Treg induction [52,53,54,55,56]. Vitamin D is also
paramount in the proper maturation of invariant natural killer T
(iNKT) cells in mice that are capable of direct cytotoxic
elimination of self-reactive cells [57]. Although the effects of
vitamin D on B cell functions and differentiation have not been
investigated extensively in human studies in vitro, vitamin D can
suppress mature B cell proliferation, B cell cytokine secretion,
plasma cell differentiation, and antibody production
[43,58,59,60,61]. Early studies have demonstrated that active
form of vitamin D (1a,25-dihydroxylcholecalciferol) can directly
enhance the expansion of monocyte and myeloid cell line derived
macrophages [62,63,64]. Vitamin D can also regulate the immune
system via cytokine modulation. Several studies have shown that
vitamin D can skew the cytokine profile from T helper (Th)1 and
Th17 to Th2 [40] and enhance interleukin (IL)-10 secretion while
reducing IL-2, IFN-c, GM-CSF levels in activated lymphocytes in
vitro [65,66,67] and in a vitamin D clinical trial [68]. Vitamin D
deficiency is also associated with decreased frequency of IL-2-
secreting CD8+ T cells [69,70]. Additionally, seasonality-driven
vitamin D3 variations in healthy adults correlate with changes in
cytokine production and phenotype in the T cell compartment
[71,72].
The goal of this study was to examine the prevalence of vitamin
D deficiency in a multiethnic cohort and to evaluate the impact of
severe vitamin D deficiency on the healthy human immune
system. This study provides potential insights for autoimmune and
infectious disease etiology and identifies correlates of vitamin D
deficiency.
Materials and Methods
Study subjects
Experiments were approved by the Institutional Review Board
at the Oklahoma Medical Research Foundation and performed in
accordance with the Helsinki Declaration. Healthy individuals
(total participants, n = 774; European-American, EA, n= 470;
Native American, NA, n= 179; African-American, AA, n= 125)
were recruited over the course of one year at 15 health control
fairs in central Oklahoma (35oN latitude). Participant demograph-
ics are summarized in Table 1. All study participants provided
written informed consent prior to enrollment. Blood specimens
were procured and medical record information including gender,
age, self-reported ethnicity; height, weight, current medication use,
and supplement use were collected. Serum was isolated and stored
at -80uC until used. Peripheral blood mononuclear cells (PBMCs)
were isolated using Lymphocyte Separation Medium (Mediatech,
Inc, Manassas, VA) and stored in freezing media (20% human
serum and 10% DMSO in RPMI) at 280uC until use. The UV
index climatological mean (UVI) for the state of Oklahoma was
calculated for each month of patient recruitment based on reports
from the United States Environmental Protection Agency (EPA)
(http://www.epa.gov/sunwise/uvimonth.html). UVB data for
single wavelength at 305 nm at noon was acquired via the US
National Aeronautics and Space Administration’s (NASA’s)
Giovanni data set (http://disc.sci.gsfc.nasa.gov/giovanni, 2013
NASA Goddard Centre, Greenbelt, MD). Monthly average of
UVB at 305 nm (slightly overestimated the prime physiological
active wavelength of 290–295 nm) in Oklahoma was used for the
further analysis. Analyses and visualization of UVB at 305 nm
data used in this publication were produced with the Giovanni
online data system, developed and maintained by NASA GES
DISC.
25(OH)D determination
Plasma 25(OH)D levels were determined in duplicate using a
commercial enzyme immunoassay (Immunodiagnostic Systems,
Inc., Scottsdale, AZ) according to manufacturer instructions,
performed at the Oklahoma Center of Biomedical Research of
Excellence (COBRE) Serum Analyte and Biomarker Core.
Vitamin D sufficiency was defined as $20 ng/mL, deficiency as
,20 ng/mL, and severely deficiency as ,12 ng/mL [73]. In
order to determine the effect of vitamin D on immune cell
functions, we identified individuals with vitamin D levels above the
80th percentile (.24.8 ng/ml) as ‘vitamin D sufficient’ and those
with vitamin D levels below the 20th percentile (,11.3 ng/ml) as
‘vitamin D severely deficient’.
Cytokine assays
A 51-plex cytokine assay was used to measure CD40L, ENA78,
eotaxin, bFGF, G-CSF, GM-CSF, gro alpha, hepatocyte growth
factor, ICAM-1, IFN-a, IFN-b, IFN-c, IL-10, IL-12p70, IL-
12p40, IL-13, IL-15, IL-17, IL-17F, IL-1a, IL-1b, IL-1RA, IL-2,
IL-4, IL-5, IL-6, IL-7, IL-8, IP10, leptin, LIF, M-CSF, MCP-1,
MCP-3, MIG, MIP-1b, MIP-1a, nerve growth factor, PAI-1,
PDGF-BB, RANTES, resistin, stem cell factor, soluble Fas ligand,
TGF-a, TGF-b, TNF-a, TNF-b, TRAIL, VCAM-1, and VEGF
in serum samples at the Stanford Human ImmuneMonitoring Center
(http://iti.stanford.edu/research/himc-protocols-immunoassays.html).
Briefly, 96-well filter-bottom plates were wet with buffer and
beads conjugated with capture antibodies for each cytokine were
added. Sera samples, cytokine standards, and control sera were
added in duplicate followed by incubation for two hours at room
temperature and then for 18 hours at 4Cu. Plates were washed and
incubated with a biotin-labeled detector antibody for two hours.
Next, the plates were washed and incubated with streptavidin-PE,
followed by a final wash and re-suspension in reading buffer.
Samples were read and data collected (100 beads per analyte) on
the Luminex MAP200 instrument (Luminex Madison, WI). Data
was analyzed using MasterPlex software (Hitachi Software
Engineering America Ltd., MiraiBio Group, San Francisco, CA).
Cytokines that fell below the detection limit of 1 pg/mL were
Vitamin D Deficiency in Healthy Individuals
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assigned a near-zero value of 0.001 pg/mL for rank-based
analyses. The cytokines that had more than 70% of the values
below the detection limit (IFN-a, IL-10, IL1a, IL-6, and M-CSF)
were excluded from the analysis. AssayChex beads (AssayChex,
Radix Biosolutions, Georgetown, TX) were used to provide
quality assurance for: addition of biotinylated detector antibodies,
addition of streptavidin-PE, instrument performance, and non-
specific background fluorescence. Both total bead count (.2000)
and individual bead counts (.40) were verified. Samples that fell
below this threshold were flagged for possible exclusion. Best-fit
standard curves for each analyte were established by the
MasterPlex software curve fit analysis, which included log-log
transformation and weighting applied to the lower end of the
curve. A plate passed quality control if the mean plate coefficient
of variation (CV) ,15%, and if not more than 20% of duplicates
have CV.25%. Mean inter-assay CV of multiplexed bead-based
assays for cytokine detection has been shown to be 10–14% in
published studies [74,75].
High sensitivity C-reactive protein (hs-CRP) was assessed using
hsCRP protein enzyme immunoassay test kit (Biomerica, Irvine,
CA) following the manufacturer’s instructions. Relative serum
concentration was calculated based on the assay-specific standard
curve generated according to the manufacturer’s instructions. The
hs-CRP assay was performed at the Oklahoma COBRE Serum
Analyte and Biomarker Core.
Flow cytometry
PBMCs were thawed in media (.80% viability was obtained),
washed twice, and re-suspended at 16107 viable cells/mL. Cells
were added to the wells (50 mL cells per well) and stained for 45
minutes at room temperature with viability stain antibodies to
surface markers for B cell (CD3, CD19, CD20, CD24, CD27,
CD38 and IgD), T cell (CD3, CD4, CD8, CD25, CD38,
CD45RA, CD45RO, CD127, CCR4, CCR7 and HLA-DR)
NK, dendritic cell (DC) and monocyte (CD3+CD19+CD20,
CD11c, CD14, CD16, CD56, CD123 and HLA-DR) subsets. A
standard panel of surface markers developed at The Stanford
Human Immune Monitoring Center was used (Stanford, CA
http://iti.stanford.edu/research/himc-protocols-flowcytometry.html).
Cells were then washed three times with FACS buffer (PBS
supplemented with 2% FBS and 0.1% sodium azide), and re-
suspended in 200 mL FACS buffer. Cells were collected (100,000
lymphocytes per sample) using DIVA 6.0 software on an LSRII
flow cytometer (BD Biosciences). Data analysis was performed
using FlowJo v9.3 (FlowJo, Ashland, OR) by gating on live cells
based on forward versus side scatter profiles, then on singlets using
forward scatter area versus height, followed by cell subset-specific
gating.
Cellular stimulation and phosphoepitope flow cytometry
PBMCs were thawed in media (.80% viability was obtained),
washed twice and re-suspended at 0.56106 viable cells/mL.
PBMCs (200 mL per well) were plated in 96-well deep-well plates.
After resting for 1 hour at 37uC, cells were stimulated by 50 mL of
Table 1. Demographics of all study participants.
Total (n = 774) European-American Native American African-American p-value
(n=470) (n =179) (n=125)
Male 246 164 (34.89%) 46 (25.70%) 36 (28.80%) 0.059
Female 528 306 (65.11%) 133 (74.30%) 89 (71.20%) -
Ageb, mean (range) 39.0 (18.0–86.0) 39.5 (19.0–86.0) 41.6 (19.0–74.0) 33.8 (18.0–62.0) ,0.001
BMIa,b, mean (range) 29.0 (16.5–58.4) 28.1 (16.5–58.4) 30.9 (18.3–56.7) 29.7 (17.4–51.6) ,0.001
Obese 236 150 (31.91%) 86 (48.04%) 53 (42.40%) ,0.001
Morbidly Obese 57 24 (5.11%) 20 (11.17%) 13 (10.40%) 0.011
aBMI = Body Mass Index; bvariables included in the multivariate regression analysis.
doi:10.1371/journal.pone.0094500.t001
Figure 1. African-Americans and Native Americans have
decreased 25(OH)D levels. (A) Median 25(OH)D levels for African-
Americans (n = 125), Native Americans (n = 179), and European-Ameri-
cans (n = 470). Error bars represent interquartile range. ***p,0.001,
Kruskal-Wallis test with Dunn’s multiple comparison; p,0.05, Shapiro-
Wilk and D’Agostino normality test. (B) Frequency of vitamin D severe
deficiency (,12 ng/mL) and vitamin D deficiency (12–20 ng/mL) in
African-Americans, Native Americans, and European Americans. Each
symbol represents one individual.
doi:10.1371/journal.pone.0094500.g001
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cytokine (IFN-a, IFN-c, IL-6, IL-7, IL-10, IL-2, or IL-21) with a
final concentration of 50 ng/mL with an exception of IFN-a,
which was 16104 units/mL, and incubated at 37uC for 15
minutes. The PBMCs were then fixed with paraformaldeyde,
permeabilized with methanol, and kept at 280uC overnight. Each
well was barcoded (stained with a unique combination of viability
stain fluorescent dyes) using a combination of Pacific Orange and
Alexa-750 (Invitrogen, Carlsbad, CA) and pooled in tubes. The
cells were washed with FACS buffer and then stained with the
following antibodies (all from BD Biosciences, San Jose, CA): CD3
Pacific Blue, CD4 PerCP-Cy5.5, CD20 PerCp-Cy5.5, CD33 PE-
Cy7, CD45RA Qdot 605, phosphorylated STAT-1 (pSTAT-1)
AlexaFluor488, pSTAT-3 AlexaFluor647, and pSTAT-5 PE. The
samples were then washed and re-suspended in FACS buffer. Data
from cells were collected (100,000 cells per stimulation condition)
using DIVA 6.0 software on an LSRII flow cytometer (BD
Biosciences). Data analysis was performed using FlowJo v9.3 by
gating on live cells based on forward versus side scatter profiles,
then on singlets using forward scatter area versus height, followed
by cell subset-specific gating. Cell stimulation and phosphoepitope
flow cytometry were performed at The Stanford Human Immune
Monitoring Center (http://iti.stanford.edu/research/himc-protocols-
flowcytometry.html).
Statistical analyses
For normally distributed data, unpaired Student’s t test was
used. Pearson’s correlations were used to analyze associations
between cytokine and 25(OH)D levels. Cytokine, 25(OH)D levels,
and a portion of phosphoflow cytometry results were non-normally
distributed; therefore Mann Whitney and/or Kruskal-Wallis tests
were performed when comparing multiple groups. Analyses were
performed using GraphPad Prism 6.02 for Windows (GraphPad
Software, San Diego, CA, USA). Multivariate logistic regression
analyses were performed using SAS STAT 9.3 and R version 3.0.2
to predict the levels of serum vitamin D based on demographic
and clinical information. In order to explicitly account for BMI,
we conducted a nonparametric analysis of covariance, where each
quantitative variable was transformed into ranks. Statistical
significance was adjusted for multiple comparison testing using
the False Discovery Rate method (FDR).
Results
Greater than half of individuals tested were vitamin D
deficient and the majority of individuals of African-
American ethnicity were vitamin D severely deficient
Plasma from 774 individuals was measured for 25(OH)D. Of
the 774 individuals tested, 290 individuals (37.5%) were sufficient,
405 individuals (39.4%) were deficient, and 179 individuals
(23.1%) were severely deficient. Median (inter quartile range
[IQR]) 25(OH)D levels of 19.70 (15.20–25.33) ng/mL for EA,
17.20 (13.10–21.80) ng/mL for NA, and 9.20 (6.55–12.40) ng/mL
for AA were observed (Figure 1A). Among the three ethnicities,
African-Americans had the lowest level of 25(OH)D. Native
Americans had significantly higher 25(OH)D levels than African-
Americans (p,0.001) and 25(OH)D levels significantly lower than
that of the European-Americans (p,0.001) (Figure 1A). The
majority (62.5%) of the entire cohort had insufficient 25(OH)D
levels and 72.8% of the African-Americans, 19.6% of the Native
Americans, and 11.3% of the European-Americans were vitamin
D deficient (Figure 1B).
Male gender, increased BMI in females, UV index in
Native Americans, and vitamin intake are associated with
vitamin D levels
Males had significantly lower levels of 25(OH)D compared to
females (p = 0.013) and were found to be 1.65 times more likely to
be vitamin D deficient as compared to females (p = 0.002, 95%
confidence interval (CI) 1.20–2.29) (Table 2). However, when
stratified by ethnicity, differences between 25(OH)D between
genders were seen only in European-Americans (Figure 2A).
Table 2. Univariate analysis of study participants with 25(OH)D values ,20 ng/mL and .20 ng/mL.
25(OH)D
,20 ng/mL .20 ng/mL Odds Ratio p-value*
n=484 n= 290 (95% CIb)
Genderd
Male 173 (70.00%) 73 (30.00%) 1.65 (1.20–2.29) 0.002
Female 311 (59.00%) 217 (41.00%) 0.60 (0.44–0.84) 0.002
Ethnicityd
European-American 244 (52.00%) 226 (48.00%) 0.29 (0.21–0.40) ,0.001
Native American 119 (66.00%) 60 (34.00%) 1.25 (0.88–1.78) 0.219
African-American 121 (97.00%) 4 (3.00%) 23.8 (8.70–65.3) ,0.001
Vitamin used 15 (33.00%) 31 (67.00%) 0.27 (0.14–0.50) ,0.001
Aged, median (range) 36 (18–84) 38 (19–86) 0.200
BMIa,d, median (range) 29 (17–58) 26 (17–50) ,0.001
Estrogen Use in femalesd 20 (32%) 43 (68%) 0.28 (0.16–0.49) ,0.001
UV indexc,{,d, median (range) 5.50 (1.50–9.00) 4.50 (1.50–9.00) 0.015
UVBd (mW/m2/nm) 46.99 (11.35–88.65) 36.81 (11.35–88.65) 0.019
*All categorical variables were analyzed by Fisher’s exact test. Continuous variables were analyzed by Mann Whitney test. { Mean UV index during month of blood draw
in Oklahoma, residence of all participants. aBMI = Body Mass Index; bCI = Confidence Interval; cUV =Ultraviolet, Vitamin use refers to self-reported multivitamin use with
vitamins containing vitamin D, or calcium with vitamin D; dvariables included in the multivariate regression analysis.
doi:10.1371/journal.pone.0094500.t002
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European-American males (n = 164) had lower levels of vitamin D
compared to females (n = 306) (males: median (IQR) 25(OH)D of
18.46 (13.50–22.35) ng/mL vs females: 21.23 (16.03–27.51) ng/
mL (p,0.0001). This suggests that the overall 25(OH)D disparity
between genders was primarily driven by European-Americans.
Vitamin D deficiency has previously been shown to be highly
associated with BMI [14,76,77,78,79]. Here, we examined the
Table 3. Multivariate logistic regression model.
Parameter Odds Ratio (95% CIb) p-value b coefficient (SEc)
25 (OH)D ,20 ng/mL
Native American Ethnicity 1.52 (1.03–2.26) 0.036 0.42 (0.20)
African-American Ethnicity 26.10 (9.40–72.50) ,0.001 3.26 (0.52)
Male gender 12.60 (2.26–69.60) 0.004 2.53 (0.87)
BMIa 1.11 (1.07–1.14) ,0.001 0.10 (0.02)
Vitamin use 0.28 (0.14–0.56) ,0.001 21.29 (0.36)
Estrogen use 0.50 (0.27–0.91) 0.025 20.70 (0.31)
BMI*Male gender 0.93 (0.88–0.99) 0.021 20.07 (0.03)
aBMI = Body Mass Index; bCI = Confidence Interval; cSE = Standard Error.
doi:10.1371/journal.pone.0094500.t003
Figure 2. Male gender in European-Americans, increased BMI in females, and UV index in Native Americans are associated with
vitamin D status. (A) Median 25(OH)D levels in males vs. females stratified by ancestral background. ****p,0.0001, Mann Whitney test; p,0.05,
Shapiro-Wilk and D’Agostino normality test. (B) Median 25(OH)D levels in normal weight (BMI,25), overweight (BMI 25–30), obese (BMI 30–40), and
morbidly obese (BMI.40) individuals stratified by gender. **p,0.01, ***p,0.001, Kruskal-Wallis test with Dunn’s multiple comparison; p,0.05,
Shapiro-Wilk and D’Agostino normality test. Error bars indicate interquartile range. (C) Mean 25(OH)D levels of individuals based upon the average UV
index during the month in which their biological sample was obtained stratified by ethnicity. Error bars indicate SD; *r2 = 0.04, p,0.05. (D) Mean
25(OH)D levels of individuals based upon the average UVB 305 nm during the month in which their biological sample was obtained stratified by
ethnicity. Error bars indicate SD.
doi:10.1371/journal.pone.0094500.g002
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association between BMI and vitamin D levels in a multiethnic
cohort stratified by gender. Although 25(OH)D deficient individ-
uals had higher BMI median than sufficient individuals in the
cohort (p,0.001, Table 2), the difference in BMI between
sufficient and deficient groups was largely accounted for in females
(p,0.05) (Figure 2B). Further, the final multivariate regression
model showed that there is a significant interaction between BMI
and gender (p = 0.021, OR (CI) = 0.93 (0.88–0.99), Table 3).
In an addition to gender and BMI, we also assessed the effect of
average monthly UV index measured by EPA, 305 nm UVB
exposure (Figure S1 in File S1), and vitamin supplement usage
(an exogenous source of vitamin D). We found a weak positive
correlation between UV index and 25(OH)D levels in Native
Americans (r2 = 0.04, p,0.05) (Figure 2C). Similarly, we
observed a trend toward a positive correlation between UVB
and 25(OH)D levels (r2 = 0.02, p = 0.06) in Native Americans
(Figure 2D). Both UV index and UVB irradiation at 305 nm
were significantly different between vitamin D sufficient and
insufficient groups (p = 0.015 and p= 0.019 respectively, Table 2).
Forty-six (5.9%) individuals reported taking supplements
containing vitamin D (Table 2). Vitamin use was included if
the self-reported medications contained multivitamins, vitamin D,
or calcium with vitamin D and excluded if vitamin complexes did
not contain vitamin D. Of the individuals reporting vitamin use,
67% had sufficient 25(OH)D levels [median (IQR):22.8 ng/mL
(18.38–26.08)] compared to 33% of those not taking vitamins
(median (IQR) 17.7 (12.23–22.88) p,0.001, OR (CI) = 0.27
(0.14–0.50), Table 2 and Figures 3A and 3B). In our cohort,
63 women reported the use of either oral contraceptives or
hormone replacement therapies containing estrogen, 87% of
which were European-American. In this group, women who
reported use of estrogen-containing therapies had significantly
higher median (IQR) 25(OH)D levels (24.15 (19.05–30.07) ng/
mL) than European-American females not taking estrogens [20.26
(15.74–26.87) ng/mL, p= 0.008, Figures 3C and 3D].
Multivariate logistic regression analysis identified
ethnicity, BMI, gender, vitamin intake, and estrogen use
as significant predictors of deficient 25(OH)D levels
Candidate factors for multivariate models were identified based
upon current knowledge of vitamin D risk factors and statistically
significant univariate analysis findings identified herein: sex,
ethnicity, age, BMI, average UV index during the month of
blood draw, reported vitamin D supplementation intake, and the
use of estrogen-containing therapies were all included as candidate
correlates of vitamin D deficiency. African-American ethnicity
[OR 26.1 (95%CI 9.4–72.5), p,0.001], BMI [OR 1.1 (1.1–1.1),
p,0.001], male gender [OR 12.6 (2.3–69.6), p = 0.004], and
Figure 3. Vitamin usage and estrogen supplementation are associated with increased vitamin D levels. (A) Percentage of individuals
that reported taking vitamins or not taking vitamins with 25(OH)D levels ,20 ng/mL or .20 ng/mL. ****p,0.0001, Fisher’s exact test. (B) Levels of
25(OH)D observed in individuals with self-reported vitamin use (n = 46) or no vitamin use (n = 728). Median 25(OH)D levels with interquartile range is
shown. ***p,0.001, Mann Whitney test; p,0.05, Shapiro-Wilk and D’Agostino normality test. (C) Percentage of European-American female study
participants that reported estrogen supplementation. *p,0.05, Fisher’s exact test. (D) Levels of 25(OH)D in European-American female study
participants with self-reported estrogen supplementation (n = 63) or no estrogen supplementation (n = 474). Median vitamin D levels with
interquartile range are shown. **p,0.01, Mann Whitney test; p,0.05, Shapiro-Wilk and D’Agostino normality test.
doi:10.1371/journal.pone.0094500.g003
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Native American ethnicity [OR 1.52 (1.03–2.26), p = 0.036] were
identified as significant independent predictors of vitamin D
deficiency. Vitamin supplementation [OR 0.28 (0.14–0.56), p,
0.001] was found to be protective against vitamin D deficiency
(Table 3). The significant interaction term between BMI and
male gender (p = 0.021, b=20.07) suggests that males with high
BMI were less likely to be vitamin D deficient compared to females
with high BMI.
Individuals with severe vitamin D deficiency had
significantly higher GM-CSF serum levels than individuals
with sufficient vitamin D
Previously published studies support the ability of vitamin D to
modify the cytokine secretion profile of lymphoid and myeloid
cells under various inflammatory states [16,80]. To further
characterize the effects of vitamin D on circulating soluble
mediators including cytokines, chemokines, growth factors, and
soluble receptors, we measured the concentrations of 52 serum
cytokines in 20 healthy individuals whose vitamin D levels were
below the 20th percentile (,11.3 ng/mL, severely deficient) and
20 healthy individuals within the 80th percentile (.24.8 ng/mL,
sufficient). To control for the potential confounding variables,
these 40 individuals were matched based on age, gender, and self-
reported ethnicity (EA). Only EA study participants were further
examined as the NA and AA study participants did not have
enough individuals with sufficient vitamin D levels to allow for
statistically significant observations. Demographics for these
individuals are described in Table 4. Initial analysis showed that
leptin, hsCRP, and GM-CSF were statistically higher (p-value,
0.05) in vitamin D severely deficient individuals compared to
vitamin D sufficient individuals (Figure 4A and Table S1 in
File S1). However, both leptin and hsCRP have been shown to be
associated with obesity [81,82]. To ensure the observed associa-
tions were independent of adiposity, BMI was used in a
conditional logistic regression analysis. This analysis showed that
the differences in leptin and hsCRP between the two groups were
confounded by BMI, whereas the difference in GM-CSF was BMI
independent (Table S1 in File S1). GM-CSF concentrations
were significantly higher in vitamin D severely deficient individuals
as compared to vitamin D sufficient individuals (p = 0.04,
Figure 4B). This observation is consistent with the results from
stimulation assays in vitro, where the presence of vitamin D
drastically reduced GM-CSF expression in peripheral blood
lymphocytes [83].
Severely vitamin D deficient individuals have decreased
frequency of activated CD4+ and CD8+ T cells
The presence of VDR has been observed on a variety of
immune cell subtypes indicating vitamin D plays a role in immune
cell signaling leading to their differentiation, activation, or
maintenance [49]. To fully delineate the effects of vitamin D on
immune cell frequencies and activation status in healthy individ-
uals, peripheral blood mononuclear cells (PBMCs) from 40
individuals (20 vitamin D sufficient and 20 vitamin D severely
deficient, Table 4) were immunophenotyped to assess the
expressions of surface markers on PMBCs. Vitamin D sufficient
individuals had significantly higher frequencies of activated
(CD38+/HLA-DR+) CD4+ T cells as compared to the severely
deficient vitamin D individuals at basal level (p = 0.04), as well as
significantly higher frequencies of activated (CD38+/HLA2DR+)
CD8+ T (p= 0.04) cells (Figure 5 A and B, Table S2 in File
S1). No significant differences in frequencies of B cell subsets and
monocytes were observed between the two groups (Table S2 in
File S1). These results indicate that vitamin D levels may affect T
cell subset development and the activation capacity of cytotoxic
and helper T cells in vivo.
Vitamin D severely deficient individuals demonstrate
decreased phosphorylated STAT1 in response to IL-2,
IL-10, stimulation, but increased phosphorylated STAT1
in response to IFN-c stimulation in CD4+ T cells
In order to elucidate the effects of vitamin D on CD4+ T and
CD8+ T cell responses, phosphoepitope flow cytometry assays
were performed to assess STAT1, STAT3, and STAT5
phosphorylation (pSTAT) status in the presence of both pro-
inflammatory (IFN-a, IFN-c, IL-6, IL-7, IL-2, and IL-21) and
anti-inflammatory (IL-10) cytokines.
Individuals with severely deficient vitamin D levels as compared
to individuals with sufficient vitamin D levels had an increased fold
change of pSTAT1 (Figure 6A) in their CD4+ T cells in response
to IFN-c stimulation (p,0.01, q = 0.01) (Table S3 in File S1).
Stimulation with IL-2 resulted in slightly increased fold change in
pSTAT1 in CD4+ T cells of vitamin D sufficient individuals (p,
0.01, q= 0.03, Figure 6A). CD8+ T cells from vitamin D severely
deficient individuals trended toward decreased pSTAT1 in
response to IL-2, IL-10, and IL-21 (p= 0.02 and q= 0.17, Table
S3 in File S1 and Figure 6B). These results suggest that vitamin
D can hinder the Th1 directed responses while enhancing the
cellular responses to modulatory cytokines such as IL-2, IL-10.
Table 4. Demographics of the European-American individuals selected for cellular and biomarker assays.
Parameter Severely Deficient Vitamin D Sufficient Vitamin D p-value
(n =20) (n=20)
Vitamin D, median (range) 8.95 (6.15–10.36) 40.95 (30.97–63.91) ,0.01
Gender
Male, count (%) 5 (25.00%) 5 (25.00%) 1.00
Female, count (%) 15 (75.00%) 15 (75.00%) -
Age, median (range) 43.00 (24.00–62.00) 26.50 (21.00–69.00) 0.07
UV Index{, median (range) 4.50 (1.50–8.00) 4.50 (1.50–8.00) 0.88
UVB, median (range) 36.81 (11.35–84.05) 36.81 (11.35–84.05) 0.90
BMIa, median (range) 28.92 (20.91–43.26) 23.50 (17.16–31.00) ,0.01
{Mean UV index during month of blood draw in Oklahoma, residence of all participants. aBMI = Body Mass Index.
doi:10.1371/journal.pone.0094500.t004
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B cells from vitamin D severely deficient individuals
demonstrated decreased levels of phosphorylated STAT1
in response to IL-2 and IL-10 stimulation
Several studies have implicated some suppressive effects of
vitamin D on activated B cells either directly or indirectly through
other immune cells [59,84,85]. We assessed differences in the fold-
change in phosphorylation of STATs in B cells upon various
cytokine stimulations in vitamin D severely deficient and vitamin
D sufficient individuals. B cells from vitamin D sufficient
individuals had increased pSTAT1 than vitamin D severely
deficient individuals in response to IL-2 and IL-10 stimulation
independent of BMI (p,0.001 and q,0.05, Figure 6C). These
results suggest that vitamin D can modulate B cell responses to
both anti- and pro-inflammatory stimuli.
Discussion
In this study we detected a large proportion of healthy
individuals to be vitamin D deficient (62.5%) in a multiethnic
cohort containing African-Americans, European-Americans, and
Figure 4. GM-CSF concentration was reduced in the vitamin D sufficient group. (A) Cytokine concentration ratio of vitamin D sufficient
group to vitamin D severely deficient group. **p,0.01, Mann Whitney U Test. (B) Median concentration of GM-CSF in vitamin D severely deficient
(n = 20) and sufficient groups (n = 20). *p,0.05, Mann-Whitney U Test corrected for BMI; p,0.05, Shapiro-Wilk and D’Agostino normality test. Error
bars indicate interquartile range.
doi:10.1371/journal.pone.0094500.g004
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Native Americans. While many studies have demonstrated
decreased 25(OH)D levels in African-Americans [9,10,86], this is
the first report to describe the high level of vitamin D deficiency in
Native Americans of Oklahoma.
Nearly two-thirds of the Native Americans in this study were
deficient and approximately one-third of those individuals had
severe vitamin D deficiency. Native American populations have a
six-fold increase in mortality from tuberculosis and a three-fold
increase in mortality from type 2 diabetes [87], both of which have
been associated with vitamin D deficiency [1,23,88]. Therefore,
addressing this deficiency in Native American populations is
critical.
Contrary to previous reports of vitamin D deficiency in women
[9,89], European-American men were found to have significantly
lower vitamin D levels as compared to European-American
women. This could be in part due to the use of estrogens in women
that was independently associated with sufficient 25-hydroxyvita-
min D levels. Several studies have shown an association between
oral contraceptive use and increased 25(OH)D levels [5,90].
Further, we confirmed several reports demonstrating an associa-
tion with obesity and decreased circulating 25(OH)D levels [5,8,9].
This association was seen only among females, possibly resulting
from the differences in adipose tissue distribution in males and
females.
Our study identified that 62.5% of study participants had
vitamin D deficient and 23.2% of individuals were severely
vitamin D deficient. The high prevalence of vitamin D deficiency
found in this study, combined with reported low rates of vitamin D
supplementation, emphasize the importance of increased aware-
ness and supplementation, especially in populations at increased
risk including men, obese individuals, African-Americans, and
Native Americans.
Vitamin D has recently been recognized as a potent immune
regulator [16,26,37,40,49] and is linked with the enhanced risk of
developing several systemic autoimmune conditions, such as
multiple sclerosis, rheumatoid arthritis, and systemic lupus
erythematosus [91,92]. Although the immediate effects of vitamin
D on the immune responses have been dissected in vitro, the
persistent cellular and molecular alterations in vivo during deficient
vitamin D states in healthy humans are just beginning to be
systematically addressed [71,72]. Enhanced induction of cytotoxic
T cells, Treg, Th2, and monocyte-derived macrophages by
vitamin D has been well documented in literature [40,49,58,92].
Flow cytometry analysis of the frequencies of different T and B cell
subsets and monocytes in both vitamin D severely deficient and
sufficient groups demonstrated an expansion of activated CD4+
and CD8+ T cells in the vitamin D high group (Figure 5). This
finding is consistent with previous studies indicating an association
between vitamin D and T cell activation [93,94].
Vitamin D has been shown to modulate immune responses by
altering T cells [42,43,44,45,49,50,51], naı¨ve B cells, and APCs
[46,47,48]. As such, we assessed leukocyte responses to various
immunological stimuli in both vitamin D sufficient and severely
deficient groups. Our results indicated that CD4+ T cells increased
phosphorylation of STAT1 in response to IFN-c, IL-2, and IL-10
(Figure 6). This observation was particularly intriguing, since
both a strong interferon signature and vitamin D deficiency have
been observed in individuals with autoimmune disease
[29,30,31,32,33,34,35,95,96,97,98]. The modestly increased T
cell responses to IL-2 and IL-10 along with slightly reduced
response to IFN-c in CD4+ T helper populations from the vitamin
D sufficient group suggest that the presence of vitamin D may play
a role in the attenuation of immunomodulatory responses.
The frequency of B cells was not significantly different between
vitamin D sufficient and severely deficient groups (Table S1 in
File S1). B cells from vitamin D high individuals had slightly
higher responses to IL-2 and IL-10 (Figure 6C). IL-10 is critical
for the induction and maintenance of regulatory B cells that are
capable of secreting regulatory cytokines and inducing Treg
differentiation [99,100]. The modestly increased phosphorylation
of STAT1 resulting from IL-10 stimulation in B cells from vitamin
D sufficient individuals suggests that vitamin D may potentiate
regulatory B cell induction, expansion, and maintenance. Follow-
ing phosphorylation, STAT molecules can dimerize and translo-
cate into the nucleus allowing for fine-tuning of biological
responses [101]; thus, even modest changes in phosphorylation
levels can lead to alterations in down-stream events. As this is a
nested case pilot study, further characterization of the differences
in immune responses between vitamin D sufficient and deficient
individuals is warranted.
In this study, we found that a large portion of healthy
individuals recruited in central Oklahoma (between 35oN and
37oN latitude) have vitamin D deficiency, particularly in
European-American men and in individuals of African-American
or Native American descent. To evaluate and explore biological
pathways that might be affected by extremely low levels of vitamin
D, we initially designed the immune response experiments for all
three ethnicities. However, the high prevalence of vitamin D
Figure 5. Activated CD4+ and CD8+ T cell levels are increased in
the vitamin D sufficient group. (A) Percentage of activated CD4+ T
cells (CD4+CD38+) in both vitamin D sufficient (n = 20) and severely
deficient (n = 20) groups are shown. Mann Whitney U Test. (B)
Percentage of activated CD8+ T cells (CD8+CD38+) in both vitamin D
sufficient (n = 17) and severely deficient (n = 18) groups are shown. *p,
0.05, Mann Whitney U Test; p,0.05, Shapiro-Wilk and D’Agostino
normality test. Median and interquartile range are shown.
doi:10.1371/journal.pone.0094500.g005
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Figure 6. Phosphorylated STAT1 responses to IL-2 was increased in both CD4+ T cells and B cells from vitamin D sufficient group.
(A) Median STAT1 phosphorylation (pSTAT1) fold changes after IFN-c, IL-2, IL-10, and IL-21 stimulation in CD4+ T cells from both vitamin D sufficient
(n = 11) and severely deficient (n = 11) groups. (B) Median STAT1 phosphorylation fold changes after IFN-c, IL-2, IL-10, and IL-21 stimulation in CD8+ T
cells from both vitamin D sufficient (n = 17) and deficient (n = 16) groups. (C) Median STAT1 phosphorylation fold changes after IFN-c, IL-2, IL-10, and
IL-21 stimulation in CD19+ B cells from both vitamin D sufficient (n = 11) and severely deficient (n = 11) groups. Mann Whitney U Test. *q,0.05 after
BMI and multiple testing correction; p,0.05, Shapiro-Wilk and D’Agostino normality test. Error bars indicate interquartile range.
doi:10.1371/journal.pone.0094500.g006
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deficiency in both African-American and Native American
individuals rendered a matched study design within these
demographics impossible. As such, 20 vitamin D sufficient and
20 severely vitamin D deficient European-American individuals
were selected for further study. As this is a pilot study, future
studies to further characterize and examine mechanisms behind
deficient vitamin D levels and potentially altered associated
immune responses in a larger study cohort is warranted. Despite
the limitations, our results show that low levels of vitamin D can
associated with changes T and B cell responses, indicating that the
sustained absence of sufficient vitamin D levels could contribute to
immune dysregulations. Considering the multitude of ongoing
clinical studies and trials on vitamin D supplementation in
autoimmune inflammatory and other chronic disease, our findings
may assist the community in testing immune-based, mechanistic
hypotheses in these prospective studies.
Supporting Information
File S1 Figure S1 and Tables S1–S3. Figure S1. UVB
305 nm levels in Oklahoma. UVB index of both northern and
southern extreme areas in OK state was obtained via NASA UVB
data (A). Differences in average monthly average UVB index
between these two regions were displayed (B). Error bars indicate
SEM. Table S1. Mann-Whitney analysis of cytokine concentration
between vitamin D high and low groups. Table S2. Mann-
Whitney rank-based analysis of immunophenotyping factors
between vitamin D sufficient and deficient individuals. Table S3.
Mann-Whitney rank-based analysis of phosphorylation of signal-
ing transducers after various stimulation of immune cells in
vitamin D sufficient and deficient individuals.
(DOC)
Acknowledgments
We thank all of the study participants for their time and commitment to the
study. We thank Wade DeJager, Rebecca Farris, Virginia L. Roberts, and
Wendy Klein for their technical assistance. We also acknowledge the
MODIS mission scientists and associated NASA personnel for the
production of the UVB data used in this research effort.
Author Contributions
Conceived and designed the experiments: LLR HTM EFC CGF RHS
DLK JMG JAJ. Performed the experiments: LLR RL HTM HD.
Analyzed the data: LLR RL HBS JMR DAF HTMHD JMG. Contributed
reagents/materials/analysis tools: LLR RL HBS JMR DAF HTM CGF
HD EFC RHS DLK JMG JAJ. Wrote the paper: LLR RL HBS JMR DAF
HD JMG.
References
1. Holick MF (2007) Vitamin D deficiency. N Engl J Med 357: 266–281.
2. Holick MF, Siris ES, Binkley N, Beard MK, Khan A, et al. (2005) Prevalence of
Vitamin D inadequacy among postmenopausal North American women
receiving osteoporosis therapy. J Clin Endocrinol Metab 90: 3215–3224.
3. Lips P, Hosking D, Lippuner K, Norquist JM, Wehren L, et al. (2006) The
prevalence of vitamin D inadequacy amongst women with osteoporosis: an
international epidemiological investigation. J Intern Med 260: 245–254.
4. Gordon CM, DePeter KC, Feldman HA, Grace E, Emans SJ (2004)
Prevalence of vitamin D deficiency among healthy adolescents. Arch Pediatr
Adolesc Med 158: 531–537.
5. Gagnon C, Baillargeon JP, Desmarais G, Fink GD (2010) Prevalence and
predictors of vitamin D insufficiency in women of reproductive age living in
northern latitude. Eur J Endocrinol 163: 819–824.
6. Sullivan SS, Rosen CJ, Halteman WA, Chen TC, Holick MF (2005)
Adolescent girls in Maine are at risk for vitamin D insufficiency. J Am Diet
Assoc 105: 971–974.
7. Renzaho AM, Halliday JA, Nowson C (2011) Vitamin D, obesity, and obesity-
related chronic disease among ethnic minorities: a systematic review. Nutrition
27: 868–879.
8. Forrest KY, Stuhldreher WL (2011) Prevalence and correlates of vitamin D
deficiency in US adults. Nutr Res 31: 48–54.
9. Melamed ML, Michos ED, Post W, Astor B (2008) 25-hydroxyvitamin D levels
and the risk of mortality in the general population. Arch Intern Med 168:
1629–1637.
10. Ginde AA, Liu MC, Camargo CA, Jr. (2009) Demographic differences and
trends of vitamin D insufficiency in the US population, 1988–2004. Arch
Intern Med 169: 626–632.
11. Pfeiffer CM, Sternberg MR, Schleicher RL, Haynes BM, Rybak ME, et al.
(2013) The CDC’s Second National Report on Biochemical Indicators of Diet
and Nutrition in the U.S. Population is a valuable tool for researchers and
policy makers. J Nutr 143: 938S–947S.
12. Engelsen O (2010) The relationship between ultraviolet radiation exposure and
vitamin D status. Nutrients 2: 482–495.
13. Matsuoka LY, Wortsman J, Haddad JG, Kolm P, Hollis BW (1991) Racial
pigmentation and the cutaneous synthesis of vitamin D. Arch Dermatol 127:
536–538.
14. Arunabh S, Pollack S, Yeh J, Aloia JF (2003) Body fat content and 25-
hydroxyvitamin D levels in healthy women. J Clin Endocrinol Metab 88: 157–
161.
15. Baeke F, Gysemans C, Korf H, Mathieu C (2010) Vitamin D insufficiency:
implications for the immune system. Pediatr Nephrol 25: 1597–1606.
16. Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C (2010) Vitamin D:
modulator of the immune system. Curr Opin Pharmacol 10: 482–496.
17. Bruce D, Whitcomb JP, August A, McDowell MA, Cantorna MT (2009)
Elevated non-specific immunity and normal Listeria clearance in young and
old vitamin D receptor knockout mice. Int Immunol 21: 113–122.
18. Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, et al. (2006)
Prospective study of predictors of vitamin D status and cancer incidence and
mortality in men. J Natl Cancer Inst 98: 451–459.
19. Dobnig H, Pilz S, Scharnagl H, Renner W, Seelhorst U, et al. (2008)
Independent association of low serum 25-hydroxyvitamin d and 1,25-
dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch
Intern Med 168: 1340–1349.
20. Pilz S, Dobnig H, Winklhofer-Roob B, Riedmuller G, Fischer JE, et al. (2008)
Low serum levels of 25-hydroxyvitamin D predict fatal cancer in patients
referred to coronary angiography. Cancer Epidemiol Biomarkers Prev 17:
1228–1233.
21. Norman AW (2006) Minireview: vitamin D receptor: new assignments for an
already busy receptor. Endocrinology 147: 5542–5548.
22. Merlino LA, Curtis J, Mikuls TR, Cerhan JR, Criswell LA, et al. (2004)
Vitamin D intake is inversely associated with rheumatoid arthritis: results from
the Iowa Women’s Health Study. Arthritis Rheum 50: 72–77.
23. Pittas AG, Lau J, Hu FB, Dawson-Hughes B (2007) The role of vitamin D and
calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin
Endocrinol Metab 92: 2017–2029.
24. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A (2006) Serum 25-
hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296: 2832–2838.
25. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM (2001) Intake
of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 358:
1500–1503.
26. Aranow C (2011) Vitamin D and the immune system. J Investig Med 59: 881–
886.
27. Grange JM, Davies PD, Brown RC, Woodhead JS, Kardjito T (1985) A study
of vitamin D levels in Indonesian patients with untreated pulmonary
tuberculosis. Tubercle 66: 187–191.
28. Davies PD, Brown RC, Woodhead JS (1985) Serum concentrations of vitamin
D metabolites in untreated tuberculosis. Thorax 40: 187–190.
29. Adorini L, Penna G (2008) Control of autoimmune diseases by the vitamin D
endocrine system. Nat Clin Pract Rheumatol 4: 404–412.
30. Bonakdar ZS, Jahanshahifar L, Jahanshahifar F, Gholamrezaei A (2011)
Vitamin D deficiency and its association with disease activity in new cases of
systemic lupus erythematosus. Lupus 20: 1155–1160.
31. Davidson A, Diamond B (2001) Autoimmune diseases. N Engl J Med 345:
340–350.
32. Milovanovic M, Heine G, Hallatschek W, Opitz B, Radbruch A, et al. (2010)
Vitamin D receptor binds to the epsilon germline gene promoter and exhibits
transrepressive activity. J Allergy Clin Immunol 126: 1016–1023, 1023 e1011–
1014.
33. Pei FH, Wang YJ, Gao SL, Liu BR, Du YJ, et al. (2011) Vitamin D receptor
gene polymorphism and ulcerative colitis susceptibility in Han Chinese. J Dig
Dis 12: 90–98.
34. Raghuwanshi A, Joshi SS, Christakos S (2008) Vitamin D and multiple
sclerosis. J Cell Biochem 105: 338–343.
35. Kamen D, Aranow C (2008) Vitamin D in systemic lupus erythematosus. Curr
Opin Rheumatol 20: 532–537.
36. Ben-Zvi I, Aranow C, Mackay M, Stanevsky A, Kamen DL, et al. (2010) The
impact of vitamin D on dendritic cell function in patients with systemic lupus
erythematosus. PLoS One 5: e9193.
Vitamin D Deficiency in Healthy Individuals
PLOS ONE | www.plosone.org 11 April 2014 | Volume 9 | Issue 4 | e94500
37. Lerman M, Burnham J, Behrens E (2011) 1,25 dihydroxyvitamin D3 limits
monocyte maturation in lupus sera. Lupus 20: 749–753.
38. Lemire JM, Adams JS, Sakai R, Jordan SC (1984) 1 alpha,25-dihydroxyvita-
min D3 suppresses proliferation and immunoglobulin production by normal
human peripheral blood mononuclear cells. J Clin Invest 74: 657–661.
39. Linker-Israeli M, Elstner E, Klinenberg JR, Wallace DJ, Koeffler HP (2001)
Vitamin D(3) and its synthetic analogs inhibit the spontaneous in vitro
immunoglobulin production by SLE-derived PBMC. Clin Immunol 99: 82–93.
40. Hewison M (2012) Vitamin D and immune function: an overview. Proc Nutr
Soc 71: 50–61.
41. Hewison M (2012) Vitamin D and immune function: autocrine, paracrine or
endocrine? Scand J Clin Lab Invest Suppl 243: 92–102.
42. Mattner F, Smiroldo S, Galbiati F, Muller M, Di Lucia P, et al. (2000)
Inhibition of Th1 development and treatment of chronic-relapsing experimen-
tal allergic encephalomyelitis by a non-hypercalcemic analogue of 1,25-
dihydroxyvitamin D(3). Eur J Immunol 30: 498–508.
43. Terrier B, Derian N, Schoindre Y, Chaara W, Geri G, et al. (2012) Restoration
of regulatory and effector T cell balance and B cell homeostasis in systemic
lupus erythematosus patients through vitamin D supplementation. Arthritis Res
Ther 14: R221.
44. Chang SH, Chung Y, Dong C (2010) Vitamin D suppresses Th17 cytokine
production by inducing C/EBP homologous protein (CHOP) expression. J Biol
Chem 285: 38751–38755.
45. Ikeda U, Wakita D, Ohkuri T, Chamoto K, Kitamura H, et al. (2010)
1alpha,25-Dihydroxyvitamin D3 and all-trans retinoic acid synergistically
inhibit the differentiation and expansion of Th17 cells. Immunol Lett 134: 7–
16.
46. Geldmeyer-Hilt K, Heine G, Hartmann B, Baumgrass R, Radbruch A, et al.
(2011) 1,25-dihydroxyvitamin D3 impairs NF-kappaB activation in human
naive B cells. Biochem Biophys Res Commun 407: 699–702.
47. Griffin MD, Dong X, Kumar R (2007) Vitamin D receptor-mediated
suppression of RelB in antigen presenting cells: a paradigm for ligand-
augmented negative transcriptional regulation. Arch Biochem Biophys 460:
218–226.
48. Griffin MD, Lutz W, Phan VA, Bachman LA, McKean DJ, et al. (2001)
Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a
vitamin D receptor-dependent pathway that promotes a persistent state of
immaturity in vitro and in vivo. Proc Natl Acad Sci U S A 98: 6800–6805.
49. Peelen E, Knippenberg S, Muris AH, Thewissen M, Smolders J, et al. (2011)
Effects of vitamin D on the peripheral adaptive immune system: a review.
Autoimmun Rev 10: 733–743.
50. Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, et al. (2001)
1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to
enhance the development of Th2 cells. J Immunol 167: 4974–4980.
51. Barrat FJ, Cua DJ, Boonstra A, Richards DF, Crain C, et al. (2002) In vitro
generation of interleukin 10-producing regulatory CD4(+) T cells is induced by
immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-
inducing cytokines. J Exp Med 195: 603–616.
52. Bilate AM, Lafaille JJ (2012) Induced CD4+Foxp3+ regulatory T cells in
immune tolerance. Annu Rev Immunol 30: 733–758.
53. Kang SW, Kim SH, Lee N, Lee WW, Hwang KA, et al. (2012) 1,25-
Dihyroxyvitamin D3 promotes FOXP3 expression via binding to vitamin D
response elements in its conserved noncoding sequence region. J Immunol 188:
5276–5282.
54. Farias AS, Spagnol GS, Bordeaux-Rego P, Oliveira CO, Fontana AG, et al.
(2013) Vitamin D3 induces IDO(+) tolerogenic DCs and enhances Treg,
reducing the severity of EAE. CNS Neurosci Ther 19: 269–277.
55. Gregori S, Giarratana N, Smiroldo S, Uskokovic M, Adorini L (2002) A
1alpha,25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and
arrests autoimmune diabetes in NOD mice. Diabetes 51: 1367–1374.
56. Correale J, Ysrraelit MC, Gaitan MI (2009) Immunomodulatory effects of
Vitamin D in multiple sclerosis. Brain 132: 1146–1160.
57. Yu S, Zhao J, Cantorna MT (2011) Invariant NKT cell defects in vitamin D
receptor knockout mice prevents experimental lung inflammation. J Immunol
187: 4907–4912.
58. Muller K, Bendtzen K (1996) 1,25-Dihydroxyvitamin D3 as a natural regulator
of human immune functions. J Investig Dermatol Symp Proc 1: 68–71.
59. Chen S, Sims GP, Chen XX, Gu YY, Lipsky PE (2007) Modulatory effects of
1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 179:
1634–1647.
60. Knippenberg S, Smolders J, Thewissen M, Peelen E, Tervaert JW, et al. (2011)
Effect of vitamin D(3) supplementation on peripheral B cell differentiation and
isotype switching in patients with multiple sclerosis. Mult Scler 17: 1418–1423.
61. Abou-Raya A, Abou-Raya S, Helmii M (2013) The effect of vitamin D
supplementation on inflammatory and hemostatic markers and disease activity
in patients with systemic lupus erythematosus: a randomized placebo-
controlled trial. J Rheumatol 40: 265–272.
62. Griffin MD, Xing N, Kumar R (2003) Vitamin D and its analogs as regulators
of immune activation and antigen presentation. Annu Rev Nutr 23: 117–145.
63. Bar-Shavit Z, Teitelbaum SL, Reitsma P, Hall A, Pegg LE, et al. (1983)
Induction of monocytic differentiation and bone resorption by 1,25-
dihydroxyvitamin D3. Proc Natl Acad Sci U S A 80: 5907–5911.
64. Abe E, Miyaura C, Sakagami H, Takeda M, Konno K, et al. (1981)
Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-
dihydroxyvitamin D3. Proc Natl Acad Sci U S A 78: 4990–4994.
65. Heine G, Niesner U, Chang HD, Steinmeyer A, Zugel U, et al. (2008) 1,25-
dihydroxyvitamin D(3) promotes IL-10 production in human B cells.
Eur J Immunol 38: 2210–2218.
66. Bhalla AK, Amento EP, Krane SM (1986) Differential effects of 1,25-
dihydroxyvitamin D3 on human lymphocytes and monocyte/macrophages:
inhibition of interleukin-2 and augmentation of interleukin-1 production. Cell
Immunol 98: 311–322.
67. Towers TL, Freedman LP (1998) Granulocyte-macrophage colony-stimulating
factor gene transcription is directly repressed by the vitamin D3 receptor.
Implications for allosteric influences on nuclear receptor structure and function
by a DNA element. J Biol Chem 273: 10338–10348.
68. Yusupov E, Li-Ng M, Pollack S, Yeh JK, Mikhail M, et al. (2010) Vitamin d
and serum cytokines in a randomized clinical trial. Int J Endocrinol 2010.
69. Thien R, Baier K, Pietschmann P, Peterlik M, Willheim M (2005) Interactions
of 1 alpha,25-dihydroxyvitamin D3 with IL-12 and IL-4 on cytokine expression
of human T lymphocytes. J Allergy Clin Immunol 116: 683–689.
70. Willheim M, Thien R, Schrattbauer K, Bajna E, Holub M, et al. (1999)
Regulatory effects of 1alpha,25-dihydroxyvitamin D3 on the cytokine
production of human peripheral blood lymphocytes. J Clin Endocrinol Metab
84: 3739–3744.
71. Khoo AL, Koenen HJ, Chai LY, Sweep FC, Netea MG, et al. (2012) Seasonal
variation in vitamin D(3) levels is paralleled by changes in the peripheral blood
human T cell compartment. PLoS One 7: e29250.
72. Khoo AL, Chai LY, Koenen HJ, Sweep FC, Joosten I, et al. (2011) Regulation
of cytokine responses by seasonality of vitamin D status in healthy individuals.
Clin Exp Immunol 164: 72–79.
73. Committee to Review Dietary Reference Intakes for Vitam D and Calcium
IoM (2011) Dietary Reference Intakes for Calcium and Vitamin DWashington,
D.C.: The National Academies Press. 1–1116 p.
74. du Pont NC, Wang K, Wadhwa PD, Culhane JF, Nelson EL (2005) Validation
and comparison of luminex multiplex cytokine analysis kits with ELISA:
determinations of a panel of nine cytokines in clinical sample culture
supernatants. J Reprod Immunol 66: 175–191.
75. Dossus L, Becker S, Achaintre D, Kaaks R, Rinaldi S (2009) Validity of
multiplex-based assays for cytokine measurements in serum and plasma from
"non-diseased" subjects: comparison with ELISA. J Immunol Methods 350:
125–132.
76. Drincic AT, Armas LA, Van Diest EE, Heaney RP (2012) Volumetric dilution,
rather than sequestration best explains the low vitamin D status of obesity.
Obesity (Silver Spring) 20: 1444–1448.
77. Kimmons JE, Blanck HM, Tohill BC, Zhang J, Khan LK (2006) Associations
between body mass index and the prevalence of low micronutrient levels
among US adults. MedGenMed 8: 59.
78. Parikh SJ, Edelman M, Uwaifo GI, Freedman RJ, Semega-Janneh M, et al.
(2004) The relationship between obesity and serum 1,25-dihydroxy vitamin D
concentrations in healthy adults. J Clin Endocrinol Metab 89: 1196–1199.
79. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF (2000) Decreased
bioavailability of vitamin D in obesity. Am J Clin Nutr 72: 690–693.
80. Coussens AK, Wilkinson RJ, Hanifa Y, Nikolayevskyy V, Elkington PT, et al.
(2012) Vitamin D accelerates resolution of inflammatory responses during
tuberculosis treatment. Proc Natl Acad Sci U S A 109: 15449–15454.
81. Cottam D, Fisher B, Ziemba A, Atkinson J, Grace B, et al. (2010) Tumor
growth factor expression in obesity and changes in expression with weight loss:
another cause of increased virulence and incidence of cancer in obesity. Surg
Obes Relat Dis 6: 538–541.
82. Unek IT, Bayraktar F, Solmaz D, Ellidokuz H, Sisman AR, et al. (2010) The
levels of soluble CD40 ligand and C-reactive protein in normal weight,
overweight and obese people. Clin Med Res 8: 89–95.
83. Tobler A, Gasson J, Reichel H, Norman AW, Koeffler HP (1987) Granulocyte-
macrophage colony-stimulating factor. Sensitive and receptor-mediated
regulation by 1,25-dihydroxyvitamin D3 in normal human peripheral blood
lymphocytes. J Clin Invest 79: 1700–1705.
84. Muller K, Heilmann C, Poulsen LK, Barington T, Bendtzen K (1991) The role
of monocytes and T cells in 1,25-dihydroxyvitamin D3 mediated inhibition of
B cell function in vitro. Immunopharmacology 21: 121–128.
85. Heine G, Anton K, Henz BM, Worm M (2002) 1alpha,25-dihydroxyvitamin
D3 inhibits anti-CD40 plus IL-4-mediated IgE production in vitro.
Eur J Immunol 32: 3395–3404.
86. Nesby-O’Dell S, Scanlon KS, Cogswell ME, Gillespie C, Hollis BW, et al.
(2002) Hypovitaminosis D prevalence and determinants among African
American and white women of reproductive age: third National Health and
Nutrition Examination Survey, 1988–1994. Am J Clin Nutr 76: 187–192.
87. IHS (2011) Indian Health Service Health Disparities. http://info.ihs.gov/
health/health_index.asp: Accessed March 2011.
88. Nnoaham KE, Clarke A (2008) Low serum vitamin D levels and tuberculosis: a
systematic review and meta-analysis. Int J Epidemiol 37: 113–119.
89. Scragg R, Camargo CA, Jr. (2008) Frequency of leisure-time physical activity
and serum 25-hydroxyvitamin D levels in the US population: results from the
Third National Health and Nutrition Examination Survey. Am J Epidemiol
168: 577–586; discussion 587–591.
Vitamin D Deficiency in Healthy Individuals
PLOS ONE | www.plosone.org 12 April 2014 | Volume 9 | Issue 4 | e94500
90. Harris SS, Dawson-Hughes B (1998) The association of oral contraceptive use
with plasma 25-hydroxyvitamin D levels. J Am Coll Nutr 17: 282–284.
91. Pelajo CF, Lopez-Benitez JM, Miller LC (2010) Vitamin D and autoimmune
rheumatologic disorders. Autoimmun Rev 9: 507–510.
92. Bikle DD (2011) Vitamin D regulation of immune function. Vitam Horm 86:
1–21.
93. von Essen MR, Kongsbak M, Schjerling P, Olgaard K, Odum N, et al. (2010)
Vitamin D controls T cell antigen receptor signaling and activation of human T
cells. Nat Immunol 11: 344–349.
94. Smolders J, Thewissen M, Damoiseaux J (2011) Control of T cell activation by
vitamin D. Nat Immunol 12: 3; author reply 3–4.
95. Sozzani S, Bosisio D, Scarsi M, Tincani A (2010) Type I interferons in systemic
autoimmunity. Autoimmunity 43: 196–203.
96. Kamen DL, Aranow C (2008) The link between vitamin D deficiency and
systemic lupus erythematosus. Curr Rheumatol Rep 10: 273–280.
97. Wright TB, Shults J, Leonard MB, Zemel BS, Burnham JM (2009)
Hypovitaminosis D is associated with greater body mass index and disease
activity in pediatric systemic lupus erythematosus. J Pediatr 155: 260–265.
98. von Scheven E, Burnham JM (2011) Vitamin D supplementation in the
pediatric rheumatology clinic. Curr Rheumatol Rep 13: 110–116.
99. Yoshizaki A, Miyagaki T, DiLillo DJ, Matsushita T, Horikawa M, et al. (2012)
Regulatory B cells control T-cell autoimmunity through IL-21-dependent
cognate interactions. Nature 491: 264–268.
100. Carter NA, Vasconcellos R, Rosser EC, Tulone C, Munoz-Suano A, et al.
(2011) Mice lacking endogenous IL-10-producing regulatory B cells develop
exacerbated disease and present with an increased frequency of Th1/Th17 but
a decrease in regulatory T cells. J Immunol 186: 5569–5579.
101. O’Shea JJ, Holland SM, Staudt LM (2013) JAKs and STATs in immunity,
immunodeficiency, and cancer. N Engl J Med 368: 161–170.
Vitamin D Deficiency in Healthy Individuals
PLOS ONE | www.plosone.org 13 April 2014 | Volume 9 | Issue 4 | e94500
